Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia

Completed

Conditions: Obesity and Cardiovascular Risk

Interventions: Other: No treatment given

First Posted Date: 2022-12-08

Last Posted Date: 2024-02-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1144

Registration Number: NCT05642533

Locations: 🇸🇦
King Abdul Aziz University Hospital - Jeddah, Jeddah, Saudi Arabia
🇸🇦
King Abdulaziz Hospital-Al Ahsa-National Guard, Al Ahsa, Saudi Arabia
🇸🇦
King Khaled University Hospital,King Saud Univ. Med. City, Riyadh, Saudi Arabia

and more 2 locations

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Phase 3

Recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Ziltivekimab

First Posted Date: 2022-12-05

Last Posted Date: 2024-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 5600

Registration Number: NCT05636176

Locations: 🇺🇸
Advanced Cardiovascular, LLC, Alexander City, Alabama, United States
🇺🇸
Northwest Heart Clin. Res., Arlington Heights, Illinois, United States
🇺🇸
Tennova HC Turkey Creek MC, Knoxville, Tennessee, United States

and more 786 locations

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: NNC0582-0001
Drug: Placebo

First Posted Date: 2022-11-22

Last Posted Date: 2023-11-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT05624580

Locations: 🇦🇹
Clinical Trials Unit / Center for Medical Research, Graz, Austria

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

Recruiting

Conditions: Haemophilia A

Interventions: Drug: Esperoct

First Posted Date: 2022-11-18

Last Posted Date: 2024-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 100

Registration Number: NCT05621746

Locations: 🇨🇦
Novo Nordisk Investigational Site, Hamilton, Ontario, Canada

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

Phase 1

Recruiting

Conditions: Healthy Volunteers
Hepatic Steatosis

Interventions: Drug: NNC0581-0001
Drug: Placebo (NNC0581-0001)

First Posted Date: 2022-10-31

Last Posted Date: 2024-05-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT05599945

Locations: 🇬🇧
Parexel CPRU, Level 7, Harrow, Middlesex, United Kingdom

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Phase 4

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Semaglutide
Drug: Orlistat
Drug: Phentermine/Topiramate
Drug: Naltrexone/Bupropion
Drug: Liraglutide

First Posted Date: 2022-10-13

Last Posted Date: 2024-01-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 500

Registration Number: NCT05579249

Locations: 🇺🇸
Nutrition Research Centre, Loma Linda, California, United States

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Cagrilintide
Drug: Placebo cagrilintide
Drug: Placebo semaglutide
Drug: Semaglutide

First Posted Date: 2022-10-05

Last Posted Date: 2024-12-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3400

Registration Number: NCT05567796

Locations: 🇦🇺
Momentum Clinical Research Darlinghurst, Darlinghurst, New South Wales, Australia
🇮🇹
Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States

and more 216 locations

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

Phase 3

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Semaglutide
Drug: Placebo semaglutide

First Posted Date: 2022-10-03

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 307

Registration Number: NCT05564117

Locations: 🇺🇸
Washington Cntr Weight Mgmt, Arlington, Virginia, United States
🇩🇪
Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz, Lingen, Germany
🇵🇱
Centrum Zdrowia Metabolicznego, Poznan, Wielkopolskie Voivodeship, Poland

and more 19 locations

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

Phase 1

Active, not recruiting

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Cagrilintide

First Posted Date: 2022-10-03

Last Posted Date: 2024-12-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT05564104

Locations: 🇩🇪
APEX Research, München, Germany
🇸🇰
Summit Clinical Research s.r.o., Malacky, Slovakia

A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2022-09-15

Last Posted Date: 2024-06-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3000

Registration Number: NCT05542420

Locations: 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy